treS Resolved · high auto-curated

H37Rv Rv0126 · MTBC0 mtbc0_000137 · 601 aa · 152670–154475 MTBC0 (+) · RefSeq NP_214640.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)trehalose synthase/amylase TreS
MTBC0 PGAP re-annotationmaltose alpha-D-glucosyltransferase
Revised (this work)Maltose alpha-D-glucosyltransferase. Pfam: Alpha-amylase (PF00128.32), Malt_amylase_C (PF16657.12).
Functional category (TubercuList)virulence, detoxification, adaptation

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 29 publications

29 TB publications mention this gene. 29 publications discuss this gene. Queried separately, 23 records carry a M. tuberculosis context and 8 a non-TB mycobacterial context (species named in the 8-record verified sample: M. smegmatis (8), M. leprae (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 29: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Improvement of 9α-hydroxyandrost-4-ene-3,17-dione production in Mycolicibacterium neoaurum by regulation of cell wall formation and transcriptional regulator PadR. doi:10.1016/j.jbiotec.2024.10.005 2024
Targeting Mycobacterium tuberculosis Persistence through Inhibition of the Trehalose Catalytic Shift. doi:10.1021/acsinfecdis.4c00138 2024
Surmounting structural barriers to tackle endemic infectious diseases. doi:10.1084/jem.20211418 2021
Extensively resistant tuberculosis, Colombia, 2006-2016. doi:10.7705/biomedica.4842 2019
Crystal structure of the TreS:Pep2 complex, initiating α-glucan synthesis in the GlgE pathway of mycobacteria. doi:10.1074/jbc.RA118.004297 2019
256 records returned by the alias sweep

Searched as: Rv0126, treS, Mb0131, MMAR_0325, MSMEG_6515 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

This count disagrees with the 29 reported above. The two come from different methods and both are shown rather than one being silently overwritten. The figure above comes from the older curated source, which missed this gene; the sweep below queries every alias of the gene in a mycobacterial context. Where they differ this way, the list below is the one you can check line by line.

PublicationJournalYear
Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study. doi:10.1007/s12325-026-03703-3 Adv Ther 2026
In vitro characterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis. doi:10.1128/aac.00260-26 Antimicrob Agents Chemother 2026
Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults. doi:10.1002/jcph.70203 J Clin Pharmacol 2026
Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.6c00123 ACS Infect Dis 2026
The ribosomal RNA synthesis ratio biomarker in Mycobacterium ulcerans for drug activity evaluation. doi:10.1186/s40249-026-01449-2 Infect Dis Poverty 2026
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis. doi:10.1038/s41467-026-71460-6 Nat Commun 2026
Correction: Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors. doi:10.1007/s40121-026-01338-z Infect Dis Ther 2026
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent. doi:10.1002/jcph.70161 J Clin Pharmacol 2026
Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis. doi:10.64898/2026.01.30.702510 bioRxiv 2026
Preparing for Tuberculosis Vaccine M72/AS01(E) Implementation: A Global Demand Forecast and Key Influential Factors. doi:10.1007/s40121-026-01319-2 Infect Dis Ther 2026
Host- and pathogen-related determinants of pulmonary versus extrapulmonary tuberculosis. doi:10.1183/16000617.0174-2025 Eur Respir Rev 2026
Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species. doi:10.1021/acsinfecdis.5c00879 ACS Infect Dis 2026
Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131-1138]. doi:10.1016/j.cmi.2025.10.001 Clin Microbiol Infect 2026
Spinal tuberculosis, pathophysiology and radiological presentation, three case reports. doi:10.7705/biomedica.7685 Biomedica 2025
Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis. doi:10.1128/aac.00126-25 Antimicrob Agents Chemother 2025
Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis. doi:10.1021/acs.jmedchem.5c01331 J Med Chem 2025
Fragment-Based Development of Small Molecule Inhibitors Targeting Mycobacterium tuberculosis Cholesterol Metabolism. doi:10.1021/acs.jmedchem.5c00478 J Med Chem 2025
Sociodemographic and spatiotemporal distribution of tuberculosis and human immunodeficiency virus co-infection in three cantons of Guayas, Ecuador: A cross-sectional study. doi:10.5867/medwave.2025.03.3042 Medwave 2025
Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis. doi:10.1016/j.drup.2025.101213 Drug Resist Updat 2025
Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.4c00808 ACS Infect Dis 2025
Active search for tuberculosis in three youth detention centers in Peru. doi:10.17843/rpmesp.2024.414.13727 Rev Peru Med Exp Salud Publica 2025
Spacetime modeling of mortality by infectious and parasitic diseases in Brazil: a 20-year ecological and population-based study. doi:10.1177/20499361251313830 Ther Adv Infect Dis 2025
Fragment-based development of small molecule inhibitors targeting Mycobacterium tuberculosis cholesterol metabolism. doi:10.1101/2024.10.28.620643 bioRxiv 2024
Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis. doi:10.1101/2024.10.10.617558 bioRxiv 2024
Intestinal Tuberculosis With Recurrent Gluteal Abscesses and Perianal Fistulas: A Case Report and Literature Review. doi:10.7759/cureus.76456 Cureus 2024
Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study. doi:10.1016/S2468-2667(24)00192-0 Lancet Public Health 2024
Improvement of 9α-hydroxyandrost-4-ene-3,17-dione production in Mycolicibacterium neoaurum by regulation of cell wall formation and transcriptional regulator PadR. doi:10.1016/j.jbiotec.2024.10.005 J Biotechnol 2024
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. doi:10.1128/aac.00357-24 Antimicrob Agents Chemother 2024
Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected impacts of policy alternatives: A mathematical modeling study. doi:10.1101/2024.04.23.24306238 medRxiv 2024
Identification of kinase inhibitors as potential host-directed therapies for intracellular bacteria. doi:10.1038/s41598-024-68102-6 Sci Rep 2024
Candidate anti-tuberculosis medicines and regimens under clinical evaluation. doi:10.1016/j.cmi.2024.06.016 Clin Microbiol Infect 2024
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans. doi:10.1371/journal.pntd.0011867 PLoS Negl Trop Dis 2024
An evaluation of mental health integration in the neglected tropical diseases program in Zamfara, North-west Nigeria. doi:10.1093/inthealth/ihae003 Int Health 2024
Targeting Mycobacterium tuberculosis Persistence through Inhibition of the Trehalose Catalytic Shift. doi:10.1021/acsinfecdis.4c00138 ACS Infect Dis 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. doi:10.1128/aac.01562-23 Antimicrob Agents Chemother 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. doi:10.1038/s41591-024-02829-7 Nat Med 2024
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism. doi:10.1073/pnas.2315069121 Proc Natl Acad Sci U S A 2024
Identification and Optimization of Novel Inhibitors of the Polyketide Synthase 13 Thioesterase Domain with Antitubercular Activity. doi:10.1021/acs.jmedchem.3c01514 J Med Chem 2023
αβ,α'β'-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes. doi:10.1039/d3cc02932h Chem Commun (Camb) 2023
High-throughput screen with the l,d-transpeptidase Ldt(Mt2) of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors. doi:10.1039/d2sc06858c Chem Sci 2023
Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis. doi:10.1099/mic.0.001288 Microbiology (Reading) 2023
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. doi:10.1128/aac.01459-22 Antimicrob Agents Chemother 2023
Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. doi:10.1128/aac.01294-22 Antimicrob Agents Chemother 2023
Adenosine-Dependent Activation Mechanism of Prodrugs Targeting an Aminoacyl-tRNA Synthetase. doi:10.1021/jacs.2c04808 J Am Chem Soc 2023
A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity. doi:10.1128/AAC.02420-20 Antimicrob Agents Chemother 2023
1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.2c00392 ACS Infect Dis 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs. doi:10.1038/s41467-022-33736-5 Nat Commun 2022
Living with tuberculosis: a qualitative study of patients' experiences with disease and treatment. doi:10.1186/s12889-022-14115-7 BMC Public Health 2022
Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study. doi:10.3389/fped.2022.917731 Front Pediatr 2022
Paracoccidioidomycosis with sarcoid-like cutaneous lesion: A clinicopathological challenge. doi:10.1016/j.idcr.2022.e01574 IDCases 2022
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis. doi:10.3390/molecules27144446 Molecules 2022
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin. doi:10.1186/s13063-022-06473-9 Trials 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. doi:10.1128/aac.00132-22 Antimicrob Agents Chemother 2022
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis. doi:10.1126/scitranslmed.aaz6280 Sci Transl Med 2022
Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection. doi:10.1016/j.ejps.2022.106163 Eur J Pharm Sci 2022
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions. doi:10.1021/acsinfecdis.1c00570 ACS Infect Dis 2022
Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target. doi:10.1021/acs.jmedchem.1c01586 J Med Chem 2022
Overlapping prison/community tuberculosis outbreaks in Costa Rica revealed by alternative analysis of suboptimal material. doi:10.1111/tbed.14063 Transbound Emerg Dis 2022
Design, synthesis and SAR of antitubercular benzylpiperazine ureas. doi:10.1007/s11030-020-10158-3 Mol Divers 2022
The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation. doi:10.1016/j.tcsw.2021.100068 Cell Surf 2021
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected. doi:10.1126/scitranslmed.abg2612 Sci Transl Med 2021
A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. doi:10.1128/AAC.01514-21 Antimicrob Agents Chemother 2021
Surmounting structural barriers to tackle endemic infectious diseases. doi:10.1084/jem.20211418 J Exp Med 2021
Antimicrobial Susceptibility Testing for Mycobacterium sps in High-Throughput Format. doi:10.1007/978-1-0716-1460-0_28 Methods Mol Biol 2021
The Tuberculosis Drug Accelerator at year 10: what have we learned? doi:10.1038/s41591-021-01442-2 Nat Med 2021
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.0c00675 ACS Infect Dis 2021
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System. doi:10.1128/AAC.01914-20 Antimicrob Agents Chemother 2020
Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline. doi:10.1096/fba.2020-00022 FASEB Bioadv 2020
Synthesis and Evaluation of Antimycobacterial and Antiplasmodial Activities of Hirsutellide A and Its Analogues. doi:10.1021/acsomega.0c01065 ACS Omega 2020
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. doi:10.1021/acs.jmedchem.0c00107 J Med Chem 2020
Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors. doi:10.1016/j.bmcl.2020.127192 Bioorg Med Chem Lett 2020
MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.0c00003 J Med Chem 2020
Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite. doi:10.1021/acsinfecdis.9b00493 ACS Infect Dis 2020
Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity. doi:10.1021/acs.jmedchem.9b01561 J Med Chem 2020
Assessment of antibodies against three zoonotic bacteria and associated risk factors in pig farms in Colombia. doi:10.20506/rst.39.3.3188 Rev Sci Tech 2020
Tuberculosis outbreak caused by Mycobacterium caprae in a rabbit farm in Spain. doi:10.1111/tbed.13366 Transbound Emerg Dis 2020
Extensively resistant tuberculosis, Colombia, 2006-2016. doi:10.7705/biomedica.4842 Biomedica 2019
Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis. doi:10.1021/acsmedchemlett.9b00204 ACS Med Chem Lett 2019
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV. doi:10.1021/acs.biochem.9b00805 Biochemistry 2019
Tuberculosis: knowledge among nursing undergraduate students. doi:10.1590/0034-7167-2018-0384 Rev Bras Enferm 2019
Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.9b00112 ACS Infect Dis 2019
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. doi:10.1128/AAC.00240-19 Antimicrob Agents Chemother 2019
Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence. doi:10.1126/sciadv.aav2104 Sci Adv 2019
Crystal structure of the TreS:Pep2 complex, initiating α-glucan synthesis in the GlgE pathway of mycobacteria. doi:10.1074/jbc.RA118.004297 names it J Biol Chem 2019
The Diversified O-Superfamily in Californiconus californicus Presents a Conotoxin with Antimycobacterial Activity. doi:10.3390/toxins11020128 Toxins (Basel) 2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. doi:10.1371/journal.pntd.0007126 PLoS Negl Trop Dis 2019
Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis. doi:10.1016/j.ab.2018.12.004 Anal Biochem 2019
Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. doi:10.1021/acs.jmedchem.8b01356 J Med Chem 2018
Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.8b01533 J Med Chem 2018
Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. doi:10.1016/j.bmcl.2018.09.037 Bioorg Med Chem Lett 2018
Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1. doi:10.1038/s41598-018-31316-6 Sci Rep 2018
[Access to diagnosis of tuberculosis in Brazilian medium-sized municipality]. doi:10.15446/rsap.V20n1.64177 Rev Salud Publica (Bogota) 2018
Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future. doi:10.1021/acsinfecdis.8b00160 ACS Infect Dis 2018
Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach. doi:10.1038/s41598-018-31157-3 Sci Rep 2018
An efficient synthetic route for preparation of antimycobacterial wollamides and evaluation of their in vitro and in vivo efficacy. doi:10.1016/j.bmcl.2018.07.021 Bioorg Med Chem Lett 2018
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. doi:10.1021/acs.jmedchem.8b00172 J Med Chem 2018
Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. doi:10.1021/acsinfecdis.8b00035 ACS Infect Dis 2018
Synthesis, antimycobacterial activity and influence on mycobacterial InhA and PknB of 12-membered cyclodepsipeptides. doi:10.1016/j.bmc.2018.04.045 Bioorg Med Chem 2018
Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action. doi:10.1128/AAC.00083-18 Antimicrob Agents Chemother 2018
The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis. doi:10.1074/jbc.RA118.002251 J Biol Chem 2018
Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. doi:10.1038/s41598-018-22228-6 Sci Rep 2018
High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. doi:10.1126/scitranslmed.aal3973 Sci Transl Med 2018
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. doi:10.1038/s41598-018-21614-4 Sci Rep 2018
Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. doi:10.1002/cmdc.201700774 ChemMedChem 2018
In vivo potent BM635 analogue with improved drug-like properties. doi:10.1016/j.ejmech.2017.12.075 Eur J Med Chem 2018
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. doi:10.1093/jac/dkx467 J Antimicrob Chemother 2018
Assessment of Primary Health Care in the Treatment of Tuberculosis in a Brazilian Locality of the International Triple Frontier. doi:10.2174/1874434601711010124 Open Nurs J 2017
Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies. doi:10.1021/acs.jmedchem.7b01347 J Med Chem 2017
Population Structure and Local Adaptation of MAC Lung Disease Agent Mycobacterium avium subsp. hominissuis. doi:10.1093/gbe/evx183 Genome Biol Evol 2017
Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). doi:10.1021/acs.jmedchem.7b00631 J Med Chem 2017
Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface. doi:10.1038/s41598-017-09642-y Sci Rep 2017
Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening. doi:10.1038/ncomms16081 Nat Commun 2017
Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models. doi:10.1002/psp4.12226 CPT Pharmacometrics Syst Pharmacol 2017
Primary Health Care and tuberculosis: services evaluation. doi:10.1590/1980-5497201700010014 Rev Bras Epidemiol 2017
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. doi:10.1021/acsinfecdis.7b00006 ACS Infect Dis 2017
Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent. doi:10.1371/journal.pone.0176088 PLoS One 2017
Tuberculosis control program in the municipal context: performance evaluation. doi:10.1590/S1518-8787.2017051006553 Rev Saude Publica 2017
The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model. doi:10.1007/s10928-017-9508-2 J Pharmacokinet Pharmacodyn 2017
Pharmaceutical salt of BM635 with improved bioavailability. doi:10.1016/j.ejps.2016.12.003 Eur J Pharm Sci 2017
Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. doi:10.1016/j.ejmech.2016.10.014 Eur J Med Chem 2017
Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.6b00103 ACS Infect Dis 2017
A new 'golden age' for the antitubercular target InhA. doi:10.1016/j.drudis.2016.09.009 Drug Discov Today 2017
[A very abnormal PET-CT]. doi:10.1016/j.revmed.2015.12.014 Rev Med Interne 2017
Association between diabetes and tuberculosis: case-control study. doi:10.1590/S1518-8787.2016050006374 Rev Saude Publica 2016
Experience of health professionals in care of the homeless population with tuberculosis. doi:10.1590/S0080-623420160000600014 Rev Esc Enferm USP 2016
Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. doi:10.1038/srep38986 Sci Rep 2016
[Delay in tuberculosis diagnosis in adults in a city of São Paulo State, Brazil, in 2009: a cross-sectional study]. doi:10.5123/S1679-49742016000300011 Epidemiol Serv Saude 2016
Repurposing clinically approved cephalosporins for tuberculosis therapy. doi:10.1038/srep34293 Sci Rep 2016
Identification of KasA as the cellular target of an anti-tubercular scaffold. doi:10.1038/ncomms12581 Nat Commun 2016
THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. doi:10.1038/nmicrobiol.2015.6 Nat Microbiol 2016
Accuracy of probabilistic and deterministic record linkage: the case of tuberculosis. doi:10.1590/S1518-8787.2016050006327 Rev Saude Publica 2016
Metabolic Network for the Biosynthesis of Intra- and Extracellular α-Glucans Required for Virulence of Mycobacterium tuberculosis. doi:10.1371/journal.ppat.1005768 PLoS Pathog 2016
Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. doi:10.1128/AAC.01339-16 Antimicrob Agents Chemother 2016
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. doi:10.1016/j.ejps.2016.07.017 Eur J Pharm Sci 2016
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. doi:10.1371/journal.ppat.1005763 PLoS Pathog 2016
Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. doi:10.1016/j.ebiom.2016.05.006 EBioMedicine 2016
Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. doi:10.1021/acs.jmedchem.6b00245 J Med Chem 2016
Latent Tuberculosis Infection Diagnostic and Treatment Cascade among Contacts in Primary Health Care in a City of Sao Paulo State, Brazil: Cross-Sectional Study. doi:10.1371/journal.pone.0155348 PLoS One 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. doi:10.1128/AAC.02548-15 Antimicrob Agents Chemother 2016
A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus. doi:10.1111/mmi.13406 Mol Microbiol 2016
Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases. doi:10.1038/nrd.2016.51 Nat Rev Drug Discov 2016
N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity. doi:10.1002/cmdc.201600020 ChemMedChem 2016
New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold. doi:10.1016/j.ejmech.2016.02.008 Eur J Med Chem 2016
Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages. doi:10.1128/AAC.01920-15 Antimicrob Agents Chemother 2016
Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.5b00025 ACS Infect Dis 2015
A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.5b00063 ACS Infect Dis 2015
Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery. doi:10.1371/journal.pone.0142293 PLoS One 2015
Cooperative development of antimicrobials: looking back to look ahead. doi:10.1038/nrmicro3523 Nat Rev Microbiol 2015
Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif. doi:10.1128/AAC.00598-15 Antimicrob Agents Chemother 2015
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. doi:10.1093/infdis/jiu610 J Infect Dis 2015
Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection. doi:10.1128/AAC.01063-15 Antimicrob Agents Chemother 2015
Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation. doi:10.1371/journal.pone.0121492 PLoS One 2015
Antimicrobial susceptibility testing for Mycobacterium sp. doi:10.1007/978-1-4939-2450-9_15 Methods Mol Biol 2015
[Factors associated with geographic access to health services by TB patients in three State capitals in Northeast Brazil]. doi:10.1590/0102-311x00000414 Cad Saude Publica 2015
Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway. doi:10.1038/srep08026 Sci Rep 2015
Label-free DNA-based detection of Mycobacterium tuberculosis and rifampicin resistance through hydration induced stress in microcantilevers. doi:10.1021/ac504523f Anal Chem 2015
Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. doi:10.1128/AAC.03913-14 Antimicrob Agents Chemother 2015
Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. doi:10.1128/AAC.03461-14 Antimicrob Agents Chemother 2015
Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen. doi:10.1128/AAC.03588-14 Antimicrob Agents Chemother 2015
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. doi:10.1128/AAC.03705-14 Antimicrob Agents Chemother 2015
Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target. doi:10.1371/journal.pone.0113568 PLoS One 2014
Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities. doi:10.3390/nano4030813 Nanomaterials (Basel) 2014
Synthesis of α-glucan in mycobacteria involves a hetero-octameric complex of trehalose synthase TreS and Maltokinase Pep2. doi:10.1021/cb400508k names it ACS Chem Biol 2013
The structure of the Mycobacterium smegmatis trehalose synthase reveals an unusual active site configuration and acarbose-binding mode. doi:10.1093/glycob/cwt044 Glycobiology 2013
Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. doi:10.1371/journal.pone.0060933 PLoS One 2013
Flux through trehalose synthase flows from trehalose to the alpha anomer of maltose in mycobacteria. doi:10.1016/j.chembiol.2013.02.014 Chem Biol 2013
Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. doi:10.1002/cmdc.201200428 ChemMedChem 2013
Trends in bacterial trehalose metabolism and significant nodes of metabolic pathway in the direction of trehalose accumulation. doi:10.1111/1751-7915.12029 Microb Biotechnol 2013
4-Substituted thioquinolines and thiazoloquinolines: potent, selective, and Tween-80 in vitro dependent families of antitubercular agents with moderate in vivo activity. doi:10.1002/cmdc.201100309 ChemMedChem 2011
Mechanistic analysis of trehalose synthase from Mycobacterium smegmatis. doi:10.1074/jbc.M111.280362 J Biol Chem 2011
[Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection]. doi:10.1016/j.medcli.2010.02.038 Med Clin (Barc) 2010
Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an alpha-glucan pathway. doi:10.1038/nchembio.340 Nat Chem Biol 2010
[Three cases of panniculitis due to Mycobacterium abscessus after mesotherapy]. Actas Dermosifiliogr 2010
[Meaning of the Quantiferon TB Gold tube test in tuberculosis screening among the hospital staff in case of very old or recent positive skin tests]. doi:10.1016/j.patbio.2008.07.001 Pathol Biol (Paris) 2008
Trehalose synthase converts glycogen to trehalose. doi:10.1111/j.1742-4658.2008.06491.x FEBS J 2008
[Study of rifampin and dapsone resistance in three patients with recurring leprosy]. doi:10.1590/s1020-49892008000200001 Rev Panam Salud Publica 2008
[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. doi:10.1157/13102265 Enferm Infecc Microbiol Clin 2007
Evaluation of the incidence of preterm low birth weight in patients undergoing periodontal therapy. doi:10.1902/jop.2007.060295 J Periodontol 2007
The key role of the mycolic acid content in the functionality of the cell wall permeability barrier in Corynebacterineae. doi:10.1099/mic.0.2006/003541-0 Microbiology (Reading) 2007
[Tuberculosis, a very precarious Parisian disease]. Soins 2005
The OtsAB pathway is essential for trehalose biosynthesis in Mycobacterium tuberculosis. doi:10.1074/jbc.M414232200 J Biol Chem 2005
[Subdural empyema: an unusual presentation of neurotuberculosis]. doi:10.1016/j.revmed.2004.03.013 Rev Med Interne 2005
Trehalose synthase of Mycobacterium smegmatis: purification, cloning, expression, and properties of the enzyme. doi:10.1111/j.1432-1033.2004.04365.x Eur J Biochem 2004
[Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. doi:10.1016/s0213-005x(03)72942-5 Enferm Infecc Microbiol Clin 2003
[Tuberculous orchiepididymitis in patients with HIV infection. Presentation of three cases]. Enferm Infecc Microbiol Clin 2003
[Tuberculous peritonitis. Report of 2 cases]. An Med Interna 2002
[Comparative study of 3 tests for susceptibility of Mycobacterium tuberculosis to first-line antituberculous drugs]. Rev Esp Quimioter 2001
Duplicated gene clusters suggest an interplay of glycogen and trehalose metabolism during sequential stages of aerial mycelium development in Streptomyces coelicolor A3(2). doi:10.1007/s004380051200 Mol Gen Genet 2000
Three pathways for trehalose biosynthesis in mycobacteria. doi:10.1099/00221287-146-1-199 Microbiology (Reading) 2000
[Tuberculosis in Argentinean literature: three examples in novels, short stories, and poetry]. Hist Cienc Saude Manguinhos 1999
[Tuberculosis and HIV infection: from clinical care to prevention (third of three parts)]. An Med Interna 1997
[Tuberculosis and HIV infection: pathogenesis (2nd of 3 parts)]. An Med Interna 1997
[Tuberculosis and HIV infection: epidemiology (the first of three parts)]. An Med Interna 1997
[Cutaneous infection caused by Mycobacterium chelonae. Presentation of 3 cases with multiple lesions]. Rev Clin Esp 1996
[Evaluation of 3 culture media for isolating mycobacteria from extrapulmonary samples]. Enferm Infecc Microbiol Clin 1995
[Routine thoracic radiography at admission to a psychogeriatric hospital: why continue to perform such a procedure when it has but little effect on treatment?]. Rev Med Suisse Romande 1995
[Laryngeal tuberculosis. A report of 3 cases]. Rev Clin Esp 1995
[A very current aspect of the fate of infectious diseases: tuberculosis, leprosy and opportunistic mycobacteria]. Bull Acad Natl Med 1995
[Lupus vulgaris. Treatment with 3 drugs]. An Med Interna 1995
Experimental Reproduction of Feline Mycobacterium fortuitum Panniculitis. doi:10.1111/j.1365-3164.1994.tb00030.x Vet Dermatol 1994
[Fever of three weeks development in a 74 year-old woman with giant cell arteritis]. Med Clin (Barc) 1994
[Multiple pulmonary nodules as an unusual manifestation of pulmonary tuberculosis. Description of 3 cases]. Rev Clin Esp 1992
[Perianal ulcers of tubercular origin. A report of 3 new cases]. Rev Esp Enferm Dig 1992
[Oral tuberculosis: presentation of 3 cases]. Rev Actual Odontoestomatol Esp 1991
Bovine Nodular Thelitis: a Clinicopathological Study of 20 Cases. doi:10.1111/j.1365-3164.1990.tb00095.x Vet Dermatol 1990
[An endobronchial mass as the presentation of tuberculosis. A report of 3 cases and review of the literature]. An Med Interna 1989
[Aspergillus pneumonia in patients with chronic bronchopathy. Presentation of 3 cases]. Med Clin (Barc) 1987
[Very late complications of extrapleural pneumothorax as a result of external fistulation (on acrylic balls after 18 years) or internal fistulation (on oleothorax after 32 and 48 years, respectively)]. Rev Med Suisse Romande 1986
[Empyema caused by Aspergillus. Apropos of 3 cases]. Rev Clin Esp 1986
[Tonsillar tuberculosis. Apropos of 3 cases]. Rev Clin Esp 1982
[Atypical forms of tuberculosis. Apropos of 3 cases]. Rev Clin Esp 1980
[Tuberculosis as a cause of acute abdomen: contribution of 3 cases]. Rev Esp Enferm Apar Dig 1979
[A case of dermatomyositis with a very unusual development and histology]. Rev Rhum Mal Osteoartic 1979
[Asphyxiant pulmonary miliaria, very probably tuberculous. Difficult cure with artificial ventilation]. Nouv Presse Med 1976
[Comparison of tubercular allergy induced by 3 types of vaccine]. Bol Oficina Sanit Panam 1975
[2 epidemies of tuberculosis in children under 3 years of age, vaccinated with oral BCG vaccine, in a day nursery at São Paulo, Brazil]. doi:10.1590/s0034-89101974000300004 Rev Saude Publica 1974
[Correlation between results of slightly positive direct examination and of cultures in the diagnosis of tuberculosis]. Tunis Med 1973
[Correlation of results of slightly-positive direct diagnosis with those obtained from culture. Preliminary results]. Bull Int Union Tuberc 1973
[Clinico-pathological and immunological manifestations of sarcoidosis (apropos of 3 cases)]. Rev Clin Esp 1972
[Pott's disease in adults. Observation of 3 cases]. Prensa Med Argent 1971
[Results of 2 or 3 secondary drug combinations in the retreatment of chronic pulmonary tuberculosis]. Rev Clin Esp 1968
[Multiple cutaneous ulcerations probably due to Mycobacterium avium (considerations on paratubercular cutaneous mycobacterioses)]. Bull Soc Fr Dermatol Syphiligr 1968
[Mitral commissurotomy and pulmonary resection in the same operation. Presentation of 3 cases]. Rev Esp Tuberc 1965
[Antibiotics and pulmonary tuberculosis; chemotherapy of very long duration; chemoprophylaxis; new drugs]. Brux Med 1959
[Antibiotics & pulmonary tuberculosis: long-term chemotherapy; chemoprophylaxis; new medications]. Brux Med 1959
[Three cases of coexistence of pulmonary Brazilian paracoccidioidosis and tuberculosis]. Rev Bras Tuberc Doencas Torac 1958
[Short notes on the very early treatment of osteoarticular tuberculosis]. Rev Chir Orthop Reparatrice Appar Mot 1956
[Positiviaztion of the Mitsuda reaction after the administration of BCG in sanatoria; data on its review three years later]. Arq Min Leprol 1956
[Atypical cutaneous tuberculosis clinically very much related to Brocq-Pautrier's angiolupoid]. Bull Soc Fr Dermatol Syphiligr 1956
[Epithelioma (very probably sudoriparous) of the latero-cervical region with rapidly fatal development, associated with neoplastic miliary tuberculosis, diagnostic discussion]. Bull Soc Fr Dermatol Syphiligr 1955
[Very late purulent effusions with pleural calcifications after serofibrinous pleurisy]. Rev Tuberc 1955
[Clinical effect of prolonged and combined antibiotic therapy on parenchymatous and canalicular lesions of pulmonary tuberculosis]. Bull Mem Soc Med Hop Paris 1955
[Treatment of pulmonary tuberculosis by a very prolonged and continuous antibiotic therapy]. Sem Hop 1955
[Very rapid cure of some cases of pulmonary tuberculosis]. Bull Mem Soc Med Hop Paris 1954
[Effect of varying doses of isoniazid on advanced experimental tuberculosis in the mouse; effect of massive doses]. C R Seances Soc Biol Fil 1954
[Three cases of terminal tuberculous ureteritis]. Rev Argent Urol 1953
[A very misleading case of pulmonary bilharziasis observed in Paris]. Presse Med (1893) 1952
[Considerations on three cases of tuberculous meningitis treated with hydrazide]. Medicamenta (Madr) 1952
[Coexistent tertiary syphilis and tuberculous lupus with rapid evolution]. Bull Soc Fr Dermatol Syphiligr 1952
[Extensive subacute ulcerous tuberculosis of the oral cavity; very rapid cicatrization by isonicotinic acid hydrazide]. Bull Soc Fr Dermatol Syphiligr 1952
[Diagnostic difficulties in three cases of nephropathies; differential diagnosis from tuberculosis]. Arch Esp Urol 1952
[Our experience with the treatment of pulmonary tuberculosis with the isonicotinic acid hydrazide, rimifon, for three months]. Torax 1952
[Considerations on 3 clinical cases]. Med Contemp 1951
[Three years of BCG in newborn in the city of São João Del-Rei]. Hospital (Rio J) 1951
[Very favorable fibrinolytic action of streptokinase-streptodornase in a case of tuberculous encapsulated pleurisy]. Bull Mem Soc Med Hop Paris 1951
[Tuberculosis as an epidemiological problem; three years work at the Soledad Orozco de Avila Camacho health center]. Rev Mex Tuberc Enferm Apar Respir 1951
[Three cases of renal tuberculosis of uncommon evolution]. Rev Argent Urol 1951
[The preventorium; its concept, usefulness and organization; 3 years experience in the preventorium of the Benjamin Guimarães Foundation]. J Pediatr (Rio J) 1951
[Simultaneous presence in sputum of streptomycin-resistant and streptomycin-sensitive Koch bacilli]. Rev Tuberc 1950
[On the question of tuberculosis of the external genital organs about two very rare cases]. Acta Derm Venereol 1949
[Results of the first 10,000 abbreviations in the city of Tres Arroyos]. names it Dia Med 1948
[Vitamin C (ascorbic acid) in very high doses, administered alone or in combination with vitamin D2, in tuberculosis]. Bull Acad Natl Med 1948
[Papulo-neurotic tuberculosis and dermo-hypodermic tuberculosis very rapidly improved by intravenous vitamin C in high doses]. Bull Soc Fr Dermatol Syphiligr 1948
[Generic tree of a rural family very proven by tuberculosis]. Rev Tuberc 1947
[Acute silicosis after very short exposure to pure silica dust; late associated tuberculosis]. Rev Tuberc 1946
[Synthesis of the observations made in three countries in Latin America, in relation to the guidelines given by them to the fight against tuberculosis]. Rev Cuba Tuberc 1945

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

CRISPRi vulnerability

Vulnerability index -1.65 (95% CI -4.67 to 2.60). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.298 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=26 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionInvolved in trehalose biosynthesis (protective effect). Converts maltose to trehalose. Mycobacteria can produce trehalose from glucose 6-phosphate and UDP-glucose (the OtsA-OtsB pathway) from glycogen-like alpha(1-->4)-linked glucose polymers (the TreY-TreZ pathway) and from maltose (the TreS pathway).
Mycobrowser EC 5.4.99.- · superseded EC numbering; the atlas uses the current class (3.2.1.1, 5.4.99.16)

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0131 · 100.0% identity
M. marinum MMAR_0325 · 91.2% identity
M. smegmatis MSMEG_6515 · 85.8% identity
M. orygis RJtmp_000137 · 100.0% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WQ19 SwissProt · reviewed · Evidence at protein level
UniProt nameTrehalose synthase/amylase TreS
EC (curated) EC 3.2.1.1, EC 5.4.99.16
Curated functionCatalyzes the reversible interconversion of maltose and trehalose by transglucosylation. Also displays amylase activity, catalyzing the endohydrolysis of (1->4)-alpha-D-glucosidic linkages in glycogen and maltooligosaccharides such as maltoheptaose, to produce maltose which then can be converted to trehalose. TreS plays a key role in the utilization of trehalose for the production of glycogen and alpha-glucan via the TreS-Pep2 branch involved in the biosynthesis of maltose-1-phosphate (M1P). Might also function as a sensor and/or regulator of trehalose levels within the cell. Thus, when trehal.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category G Carbohydrate transport and metabolism
Preferred nametreS
eggNOG descriptionTrehalose synthase
Orthologous groupCOG0366
EC number EC 3.2.1.1, EC 5.4.99.16
KEGG orthology K05343
KEGG pathways map00500, map01100
CAZy family GH13
Gene Ontology (64) GO:0000023, GO:0000271, GO:0003674, GO:0003824, GO:0004553, GO:0004556, GO:0005488, GO:0005509, GO:0005575, GO:0005622, GO:0005623, GO:0005737 +52 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.206 · quasi-invariant (5 sites), pN/pS underpowered
Polymorphic sites (≥ 0.1% of strains) 3 synonymous, 2 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) 0.0 · 9 consensus substitution(s)
under purifying selection vs M. canettii (deep divergence; dN/dS=0.0) — a real, constrained gene predating the MTBC clonal expansion
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 52/53 (98%) · mean identity 87.8% · 4/4 closest MTBAP relatives
conserved across the genus (present in 52/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 10/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 46.0%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

The two screens disagree on this gene: Tn-seq says non-essential (NE), CRISPRi says essential, with an estimate its own authors flag as not certain.

Two genome-wide screens disagree on this gene, and both are kept as they stand. They do not measure the same thing: the Tn-seq call (DeJesus 2017) reports tolerance to transposon insertion across the ORF, the CRISPRi call (Bosch 2021) reports tolerance to partial knockdown. A gene can absorb an insertion and still be required at full dosage, or the reverse. Here the CRISPRi estimate is one its own authors flag as NOT certain (vulnerability index -1.651), so it is the weaker of the two calls. Do not treat the CRISPRi essentiality as settled here. Atlas-wide, 104 gene(s) fall in this exact stratum, out of 193 showing this direction of disagreement.

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 31 in the ORF — 0 in the essential state, 0 growth-defect, 31 non-essential, 0 growth-advantage. Saturation 1.000, mean read count 221.64516129. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 31 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Mutant phenotypes (conditional Tn-seq, MtbTnDB) in-vivo phenotype

Conditionlog2FCqEffect
differential fitness in a comparison whose nature could not be established (upstream metadata defect, see note) (undetermined) +5.640.0 disruption advantageous
Mutants exhibiting altered fitness in the absence of gene marP (other) -5.550.0 required
fitness in mouse infection, day 45 (in vivo) -4.510.0 required
fitness in mouse infection (in vivo) +2.910.0 disruption advantageous
fitness in mouse infection (in vivo) +2.560.048 disruption advantageous
Differential genetic requirements of clinical Mtb strain (ID=663) from Euro-American lineage (compared to H37Rv control) (strain background) +2.280.0 required
Differential genetic requirements of clinical Mtb strain (ID=632) from East Asian lineage (compared to H37Rv control) (strain background) +2.260.0 required
fitness in mouse infection (in vivo) +2.080.0075 disruption advantageous
Differential genetic requirements of clinical Mtb strain (ID=621) from East Asian lineage (compared to H37Rv control) (strain background) +1.930.013 required
Differential genetic requirements of clinical Mtb strain (ID=631) from East Asian lineage (compared to H37Rv control) (strain background) +1.900.0 required
Differential genetic requirements of clinical Mtb strain (ID=630) from Euro-American lineage (compared to H37Rv control) (strain background) +1.590.0 required
Differential genetic requirements of clinical Mtb strain (ID=662) from East Asian lineage (compared to H37Rv control) (strain background) +1.500.0 required

Conditional fitness of transposon-disruption mutants across 14 significant condition(s) — the table lists the 12 strongest by |log2FC|, not all 14 (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Provenance note on a condition above. MtbTnDB labels this condition in vivo (Collaborative Cross mouse panel) and attributes it to Smith et al. 2022, eLife 74419. Both are wrong and for the same reason: its left arm, `mbio_H37Rv`, is the saturated H37Rv reference of DeJesus et al. 2017 (mBio 8(1):e02133-16, fourteen independent Tn libraries grown in standard medium), not a mouse strain, and the upstream generator read the token before `_vs_` as a mouse-strain name. The same sample is the in vitro control of six knockout screens in the same file. Measured here on rank correlation over 3971 genes: this condition tracks the other 81 first-order in vivo conditions at rho = +0.03, where those conditions track each other at +0.270 -- it does not behave like an infection measurement. What the comparison actually is could not be established, so it is reported as undetermined rather than renamed, and it is excluded from the in vivo count of this fiche.

Provenance note on a condition above. `marP_KO_vs_marP_WT` carries no source in MtbTnDB's own metadata (col_desc.tsv leaves paper_title/paper_URL empty). Traced by the `Rv0537c` companion project (2026-09-12): Weizhen Xu, PhD thesis, Weill Cornell Medicine, 2017, hdl:1813/64728 ("Genetic Screening In Mycobacterium Tuberculosis Utilizing Transposon Insertion Sequencing"), whose abstract describes a TnSeq genetic-interaction screen naming marP. Never published as a peer-reviewed article.

Proteomics (mass spectrometry) detected

MS detectiondetected in 15 of 16 independent MS datasets
Integrated abundance502.0 ppm · rank 403/3519 (88.6th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length601 aa
Molecular weight68.6 kDa
Theoretical pI4.81
GRAVY-0.367 (hydrophilic)
Aliphatic index78.3
Aromaticity0.123
Instability index42.8 (unstable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Alpha-amylasePF00128.32 4.8e-9252–499 Alpha amylase, catalytic domain
Malt_amylase_CPF16657.12 4.7e-22505–581 Maltogenic Amylase, C-terminal domain

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 8uzh (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 2 solved

PDBMethodResolutionCoverage
8uzh X-ray diffraction 2.8 Å 98%
8uqv Electron Microscopy 3.6 Å 96%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (2 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 93.3

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
4lxf-assembly1_A 1.00 0.96 0.91 0.96 99% 96% / 100% 0.0e+00 sig 4lxf-assembly1_A Crystal structure of M. tuberculosis TreS
8uzh-assembly1_B-2 1.00 0.96 0.92 0.88 100% 95% / 92% 0.0e+00 sig 8uzh-assembly1_B-2 SUMO fused Trehalose Synthase (TreS) of Mycobacterium tuberculosis
4lxf-assembly1_B 1.00 0.98 0.89 0.98 94% 96% / 100% 8.1e-104 sig 4lxf-assembly1_B Crystal structure of M. tuberculosis TreS
8uzh-assembly1_A 1.00 0.96 0.92 0.91 100% 95% / 95% 0.0e+00 sig 8uzh-assembly1_A SUMO fused Trehalose Synthase (TreS) of Mycobacterium tuberculosis
8uqv-assembly1_D 1.00 0.99 0.90 0.99 100% 91% / 100% 9.9e-99 sig 8uqv-assembly1_D Trehalose Synthase (TreS) of Mycobacterium tuberculosis in complex with 6-TreAz compound

Foldseek search of the AlphaFold DB model (mean pLDDT 93.3, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon)

Upstream (5' on genome)pepA (+ strand, 108 bp gap)
Downstream (3' on genome)mak (+ strand, 102 bp gap)

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 2: treS · mak — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0134) exponential phase: operon of 4, Rv0125 · Rv0126 · Rv0127 · Rv0128 (coverage 29.79)
stationary phase: operon of 2, Rv0125 · Rv0126 (coverage 35.23) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: mak (maltokinase), high confidence (score 1000, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair is recorded in a curated database (pathway or complex membership) for M. tuberculosis genes themselves (score ≥ 200): a curated association, not a measurement in this organism. Its experimental-channel score is inherited from other proteomes.

Showing the 15 strongest of this gene's 46 partners at medium confidence (25 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 46 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0127 mak exp (transferred) curated maltokinase 999 1000 ctx neighborhood:771 fusion:900 cooccurence:766 experimental:997 database:900 textmining:946
Rv1563c treY curated maltooligosyl trehalose synthase 998 977 ctx cooccurence:722 database:900 textmining:948
Rv1564c treX curated maltooligosyl trehalose synthase 989 975 ctx cooccurence:537 coexpression:428 database:900 textmining:593
Rv2006 otsB1 curated trehalose-6-phosphate phosphatase OtsB 993 968 coexpression:408 database:900 textmining:794
Rv3372 otsB2 curated trehalose 6-phosphate phosphatase 991 960 database:900 textmining:807
Rv1562c treZ curated paralog malto-oligosyltrehalose trehalohydrolase 988 948 database:900 textmining:796
Rv1328 glgP curated glycogen phosphorylase 979 947 database:900 textmining:636
Rv1781c malQ curated 4-alpha-glucanotransferase 969 939 database:900 textmining:514
Rv1326c glgB curated 1,4-alpha-glucan branching protein 997 935 database:900 textmining:965
Rv2471 aglA curated paralog alpha-glucosidase AglA 936 935 database:900
Rv2402 curated trehalase 986 933 database:900 textmining:810
Rv3401 curated glycosyl hydrolase 918 913 database:900
Rv3031 curated 1,4-alpha-glucan-branching protein 936 901 database:900
Rv0125 pepA serine protease PepA 806 797 ctx neighborhood:768
Rv1327c glgE alpha-1,4-glucan:maltose-1-phosphate maltosyltransferase 988 788 ctx cooccurence:751 textmining:949

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: trehalose synthase/amylase TreS
  • MTBC0 PGAP product: maltose alpha-D-glucosyltransferase
  • Pfam (hmmscan --cut_ga): Alpha-amylase PF00128.32 (E=5e-92), Malt_amylase_C PF16657.12 (E=5e-22)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_214640.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Alpha-amylase (PF00128.32), Malt_amylase_C (PF16657.12)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0366
  • Curated reference: UniProt P9WQ19 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 93.3)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 46 functional partner(s); context anchor mak
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000137|Rv0126|treS
MNEAEHSVEHPPVQGSHVEGGVVEHPDAKDFGSAAALPADPTWFKHAVFYEVLVRAFFDASADGSGDLRGLIDRLDYLQWLGIDCIWLPPFYDSPLRDGGYDIRDFYKVLPEFGTVDDFVALVDAAHRRGIRIITDLVMNHTSESHPWFQESRRDPDGPYGDYYVWSDTSERYTDARIIFVDTEESNWSFDPVRRQFYWHRFFSHQPDLNYDNPAVQEAMIDVIRFWLGLGIDGFRLDAVPYLFEREGTNCENLPETHAFLKRVRKVVDDEFPGRVLLAEANQWPGDVVEYFGDPNTGGDECHMAFHFPLMPRIFMAVRRESRFPISEIIAQTPPIPDMAQWGIFLRNHDELTLEMVTDEERDYMYAEYAKDPRMKANVGIRRRLAPLLDNDRNQIELFTALLLSLPGSPVLYYGDEIGMGDVIWLGDRDGVRIPMQWTPDRNAGFSTANPGRLYLPPSQDPVYGYQAVNVEAQRDTSTSLLNFTRTMLAVRRRHPAFAVGAFQELGGSNPSVLAYVRQVAGDDGDTVLCVNNLSRFPQPIELDLQQWTNYTPVELTGHVEFPRIGQVPYLLTLPGHGFYWFQLTTHEVGAPPTCGGERRL